Amneal Pharmaceuticals, Inc. AMRX
21.12 USD -0.27 (-1.26%)
Regular-session close
21.78 +0.66 +3.15%
After hours · Nov 20, 6:11 PM ET
21.07 Day range 21.70
11.52 52-week range 21.88
- YTD
- +67.62%
- 1 year
- +83.33%
News
globenewswire.com Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR® BRIDGEWATER, N.J., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the European Commission (EC) has granted marketing…
seekingalpha.com Amneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps Growing Amneal Pharmaceuticals gets a buy reaffirmed, despite its sharp rally, supported by a robust pipeline, niche demand, improving margins, and projected upside. Amneal delivered a fourth consecutive…benzinga.com Leerink Partners Maintains Outperform on Amneal Pharmaceuticals, Raises Price Target to $25 Leerink Partners analyst Daniel Clark maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform and raises the price target from $23 to $25.
benzinga.com JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25 JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $24 to $25.
benzinga.com Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 Est; Raises FY2026 Sales Guidance from $3.100B-$3.200B to $3.150B-$3.250B vs $3.159B Est Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 analyst estimate. Raises FY2026 sales outlook from $3.100 billion-$3.200 billion to $3.150…
benzinga.com Amneal Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.23 Estimate, Sales $862.684M Beat $816.058M Estimate Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.23 by 13.04 percent. This is a 52.94 percent increase over earnings…
benzinga.com JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24 JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.
